 Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: The effect of adding Pabocicide to the endocrine therapy of early breast cancer

J Clin Oncol: The effect of adding Pabocicide to the endocrine therapy of early breast cancer

 Last Update: 2021-12-24
 Source: Internet
 Author: User

Tags

gastroesophageal junction cancer

muscle invasive bladder cancer

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Palbociclib is the world's first CDK4/6 kinase inhibitor approved for marketing.

Pabocinil is now approved for the treatment of advanced breast cancer

This is a prospective, randomized phase III clinical trial (PALLAS), recruiting hormone receptor positive, human epidermal growth factor receptor 2 negative early breast cancer patients, randomly divided into two groups, receiving a two-year PALLAS Bossini + adjuvant endocrine therapy or single adjuvant endocrine therapy (at least 5 years)

The primary endpoint is invasive disease-free survival (iDFS); secondary endpoints are invasive breast cancer-free survival, remote recurrence-free survival, local cancer-free survival and overall survival

IDFS rate of the two treatment groups

Over the course of three years, a total of 5796 patients were recruited from 406 centers in 21 countries around the world, of which 5761 were included in the intention-to-treat analysis

Non-invasive breast cancer survival rate

In summary, the final analysis of the PALLAS trial showed that the addition of Pabocinil to standard endocrine therapy does not further improve the prognosis of early hormone receptor-positive breast cancer

Adding Pabocinil to standard endocrine therapy does not further improve the prognosis of early hormone receptor positive breast cancer .

Original source:

Michael Gnant, et al.

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.